Cerity Partners
LGND icon

Cerity Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Cerity Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$780K Buy
+2,467
New +$581K ﹤0.01% 2151
2026
Q1 		– Sell
-1,531
Closed -$289K – 3333
2025
Q4 		$289K Buy
1,531
+79
+5% +$15.2K ﹤0.01% 2431
2025
Q3 		$257K Buy
+1,452
New +$216K ﹤0.01% 2385
2023
Q2 		– Sell
-205
Closed -$282K – 1824
2023
Q1 		$282K Buy
+205
New +$14.6K ﹤0.01% 1553
2018
Q4 		– Sell
-1,375
Closed -$236K – 537
2018
Q3 		$236K Buy
+1,375
New +$207K 0.02% 481

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's LGND Position: Q2 2026 in Review

Cerity Partners opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 2,467 shares worth $780K. The stake represents ﹤0.01% of the portfolio and ranks #2151 among its holdings. This is a return to the name: Cerity Partners previously reported a position in LGND as recently as Q4 2025.

Cerity Partners first reported a position in LGND in Q3 2018 and has held it in 5 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Cerity Partners held 2,467 shares of Ligand Pharmaceuticals worth $780K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Cerity Partners position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2151 holding.
  • Cerity Partners first reported a position in Ligand Pharmaceuticals in Q3 2018 and has held it in 5 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.